UCB SA (0NZT.L)

ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery

SOLANA BEACH, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it has entered into a multi-year license agreement with UCB (EURONEXT BRUSSELS: UCB), a global biopharmaceutical leader, to partner on drug delivery platforms for UCB’s gene therapy portfolio. “We are extremely excited to partner with UCB, a global biopharmaceutical leader, with a focus on inno